bet on lol streamers
bet on lol streamers
bet on lol streamers
Kelum Sujith Perera, the visionary founder of the Dubai-based Sri Lions, is on a mission to transform Sri Lankan rugby and sports. Fresh off the Sri Lions’ historic triumph at the Dubai Sevens Men’s International Open, Sri Lions founder Kelum Sujith Perera Perera is doubling down on his commitment to nurture talent, unite the rugby community, and create a global platform for Sri Lankan athletes. Reflecting on the team’s groundbreaking achievement, Perera expressed immense pride: “No Sri Lankan team has ever participated in the Open Men’s International category in the history of the Dubai Sevens. We started by winning the Gulf Men’s Open in 2019 and 2020, but we knew it was time to aim higher. After earning a spot in the Open Men’s International category, we worked tirelessly for three years, culminating in last year’s Plate Championship. This year, we went one step further, defeating Spain’s Esperanza in the final and bringing home the Cup. To achieve this in front of 70,000 spectators was truly remarkable.” Perera detailed how the team combined local talent with international expertise: “We blended young Sri Lankan players with world-class internationals from Fiji, South Africa, Tonga, and Australia. Players like Cecil Afrika, Branco du Preez, and Osea Kolinisau have played pivotal roles in our journey, but this year we wanted to give even more opportunities to Sri Lankan players.” Sri Lions’ qualification for the A-Division in Sri Lanka has sparked debate, with critics questioning their legitimacy. Perera tackled these concerns head-on: “We didn’t take shortcuts. Instead of paying a fee to join the A-Division directly, we competed in the B-Division and won fairly. Our victory was recognised by officials, and the tournament was conducted under a functioning Sri Lanka Rugby Union. Allegations about the tournament’s validity or disciplinary issues are baseless. We followed every protocol, and if the tournament wasn’t legitimate, why did union officials present us with the trophy?” On accusations of poaching players, Perera was clear: “Every club brings in players, but we’ve focused on creating opportunities for those who were sidelined. Players like Kevin Kutty and Tuan Zayan Sabar have found a platform with us. We even supported Sabar when CR & FC requested him for the Clifford Cup, showing that we prioritise the sport’s growth over rivalries.” A former Lumbini and Sri Lanka Under 19 player, Perera’s focus on nurturing young players is central to Sri Lions’ ethos: “Every year, over 100 players graduate from Sri Lankan schools, but most stop playing rugby. We’re changing that by providing a pathway for school leavers to develop their skills. Players like Dulaj Navodya have thrived alongside international stars, building confidence and raising their game. This exposure not only benefits them but elevates the standard of Sri Lankan rugby.” His ambitions extend far beyond rugby:“Our dream is to create a global Sri Lankan sports franchise. Beyond rugby, we’re promoting Sri Lankan sports tourism and developing multiple sports like volleyball, netball, and golf. We’re working on establishing a partnership with Fingara to give members access to world-class facilities, and we’re bringing foreign investors to build a multi-sport complex in Sri Lanka. If the government lets us maintain underutilised facilities like Sugathadasa or Diyagama, we’ll transform them into thriving hubs for rugby, football, athletics, and more.” An internationally respected referee, Perera is also exploring international opportunities: “We’re in discussions to acquire an upcoming South African club and bring it under the Sri Lions banner. This will give Sri Lankan players a chance to compete in Super Rugby and other top-tier tournaments. Imagine a Sri Lankan team playing against the Sharks or the Crusaders – that’s the level we’re aiming for.” Perera underscored the need for collaboration within Sri Lanka’s rugby community: “Rugby is bigger than any one club or individual. We need to put aside politics and personal interests and focus on building the sport together. On the field, we compete; off the field, we must unite. Some clubs didn’t release players for the national team, and that contributed to Sri Lanka’s loss to the Philippines. Imagine what we could achieve if we worked together.” For Perera, the Sri Lions are more than a team – they are a symbol of what Sri Lanka can achieve through vision and determination: “I’m not here to criticise or seek power. My goal is to elevate Sri Lankan sports and create opportunities for our players. If someone opposes us in the A-Division, we’ll find other ways to make an impact. Rugby is a beautiful game, and it has the power to unite us. Together, we can take Sri Lankan rugby to new heights.” With a clear vision and a relentless commitment to building Sri Lankan rugby, Kelum Sujith Perera is paving the way for a brighter future, both on and off the field. The Sri Lions’ success at the Dubai Sevens is just the beginning of a journey that promises to inspire generations to come.LAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. “As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It’s an honor for General Motors and Cadillac to join the world’s premier racing series, and we’re committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM’s engineering expertise and technology leadership at an entirely new level.”
CMC Publishes 2024 Sustainability ReportWARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company’s determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months. Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio commented, "We remain steadfast in our mission to advance medical science, however as CEO of the company, preservation of shareholder value remains a priority. We urge all stakeholders to consider the profound impact short selling innovative healthcare companies has on lifesaving therapies. While stock price fluctuations are part of the public market dynamics, Tevogen Bio is acutely aware of the undue influence short sellers have.” William Keane, VP of Strategic Initiatives, and graduate of the FBI National Academy stated, “We are aware and monitoring the actions of potential short selling activity targeting our company. We will continue to bring light to this situation and will work with the appropriate authorities as needed.” The company plans to provide further updates on its progress in the coming weeks. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com
NoneKulusevski's equaliser secures draw for Tottenham as Rangers remain in top eight
Biden administration to loan $6.6B to EV maker Rivian to build Georgia factory that automaker paused
None
